10:06 AM EST - Theralase® Technologies Inc. : Announced that its lead drug formulation, Rutherrin® has been proven preclinically to be activated by Metformin, a common diabetes drug, without the use of light and/or radiation. Theralase® Technologies Inc.
shares V.TLT are trading up $0.01 at $0.19.
